Arie Belldegrun - 24 May 2021 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
Director
Signature
/s/ Veer Bhavnagri, Attorney-in-Fact
Issuer symbol
ALLO
Transactions as of
24 May 2021
Net transactions value
+$6,906,583
Form type
4
Filing time
25 May 2021, 08:00:27 UTC
Previous filing
09 Jun 2021
Next filing
09 Jun 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Options Exercise $6,906,583 +379,066 +186% $18.22 583,034 24 May 2021 Direct
holding ALLO Common Stock 40,000 24 May 2021 See footnote F1
holding ALLO Common Stock 1,798,163 24 May 2021 See footnote F2
holding ALLO Common Stock 788,990 24 May 2021 See footnote F3
holding ALLO Common Stock 3,710,006 24 May 2021 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to Buy) Options Exercise $0 -379,066 -100% $0.000000* 0 24 May 2021 Common Stock 379,066 $18.22 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held in the name of Bellco Legacy LLC (Bellco Legacy). Bellco Legacy is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun.
F2 The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3 The securities are held in the name of Bellco Capital LLC, of which the reporting person is the manager.
F4 The securities are held in the name of the Belldegrun Family Trust.
F5 25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter.